Our observation that metformin is more selective to p53-mutated cells is also supported by another report showing metformin selectively inhibits tumor growth of p53-deficient colon cancer cells in vivo [19], and signifies that metformin exhibits cytotoxic effects irrespective of genetic background in neuroblastoma cells. The gene discussed is TP53; the disease is colonic neoplasm.